Medarex, Inc.
Phase II clinical trial with MDX-070 in prostate cancer announced
Published in Pharma Investments, Ventures and Law Weekly, July 25th, 2004
The phase II clinical trial is expected to enroll up to 30 patients with prostate cancer. Patients are expected to receive four biweekly doses of 1, 5, or 10 mg/kg of MDX-070 and will be assessed for tumor response based on objective tumor response and decrease in prostate specific antigen serum levels.
In the single-dose, phase I, clinical study in 18 patients with metastatic prostate cancer, the antibody was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- A.P. Pharma, Inc.
Pharmaceutical company completes common stock sale - ATS Medical, Inc.
Device firm signs definitive agreements to sell $13.1M of common stock - Abaxis, Inc.
Blood analysis systems maker to be added to Russell 2000 Index - Accumetrics, Inc.
Diagnostics company announces $13.5M financing - Aeolus Pharmaceuticals, Inc.
Incara announces 1-for-10 reverse split and name change - Alaris Medical Systems
ICU Medical announces court order in patent infringement lawsuit - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
